Immunostimulants drugs for COVID-19: living meta-analysis of clinical studies

Table Graph

Immunostimulants drugs - versus standard of care - for COVID-19 severe or critically pdf xlsx method abbreviations

Outcome	Relative effect 95%CI	Trt. better when	I2	k (RCT/OBS)	Bayesian probability	Overall ROB	Publication bias	Degree of certainty	Endpoint importance	Published MA
efficacy endpoints 00
death D28	1.03 [0.68, 1.55]	< 1	0%	7 studies (7/-)	44.6 %	some concern	serious	moderate	crucial	-
deaths	0.90 [0.72, 1.14]	< 1	6%	14 studies (14/-)	80.8 %	low	low	high	crucial	-
deaths (time to event analysis only)	3.20 [0.62, 16.39]	< 1	0%	1 study (1/-)	8.2 %	NA	not evaluable		crucial	-
clinical deterioration	0.63 [0.29, 1.40]	< 1	0%	1 study (1/-)	87.0 %	NA	not evaluable		important	-
clinical improvement	1.61 [0.96, 2.70]	> 1	69%	5 studies (5/-)	96.5 %	some concern	serious	moderate	important	-
clinical improvement (14-day)	2.27 [0.90, 5.72]	> 1	0%	1 study (1/-)	95.9 %	NA	not evaluable		important	-
clinical improvement (28-day)	1.61 [0.69, 3.76]	> 1	74%	3 studies (3/-)	86.2 %	some concern	not evaluable	moderate	important	-
clinical improvement (7-day)	0.98 [0.27, 3.58]	> 1	0%	1 study (1/-)	48.8 %	NA	not evaluable		important	-
clinical improvement (time to event analysis only)	1.83 [1.24, 2.70]	> 1	9%	4 studies (4/-)	99.9 %	some concern	not evaluable	moderate	important	-
hospital discharge	3.44 [0.64, 18.49]	> 1	0%	1 study (1/-)	92.4 %	NA	not evaluable		important	-
mechanical ventilation	0.92 [0.54, 1.56]	< 1	0%	5 studies (5/-)	62.5 %	some concern	not evaluable	moderate	important	-
mechanical ventilation (time to event analysis only)	0.66 [0.25, 1.72]	< 1	0%	1 study (1/-)	80.2 %	NA	not evaluable		important	-
radiologic improvement (14-day)	2.33 [0.45, 12.00]	> 1	0%	1 study (1/-)	84.4 %	NA	not evaluable		important	-
viral clearance	6.97 [0.23, 210.35]	> 1	89%	2 studies (2/-)	86.4 %	some concern	not evaluable	moderate	important	-
viral clearance by day 14	7.68 [0.34, 173.70]	> 1	90%	2 studies (2/-)	89.7 %	some concern	not evaluable	moderate	important	-
ICU admission	0.60 [0.36, 0.98]	< 1	0%	5 studies (5/-)	97.9 %	some concern	not evaluable	moderate	non important	-
safety endpoints 00
serious adverse events	1.43 [0.81, 2.53]	< 1	48%	3 studies (3/-)	11.0 %	some concern	not evaluable	moderate	important	-
superinfection	0.18 [0.02, 1.59]	< 1	0%	1 study (1/-)	93.8 %	NA	not evaluable		important	-
adverse events	1.10 [0.87, 1.39]	< 1	0%	2 studies (2/-)	21.8 %	some concern	not evaluable	moderate	non important	-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.

Immunostimulants drugs - versus standard of care - for COVID-19 severe or critically pdf xlsx method abbreviations

efficacy endpoints 00

safety endpoints 00